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Surface modiﬁcation of implantable biomaterials with biologically active functionalities, including antimicrobials,
has wide potential for addressing implant-related design problems. Here, four polymerizable vancomycin derivatives
bearing either acrylamide or poly(ethylene glycol) (PEG)-acrylate were synthesized and then polymerized through
a surface-mediated reaction. Functionalization of vancomycin at either the V3 or the X1 position decreased
monomeric activity by 6-75-fold depending on the modiﬁcation site and the nature of the adduct (P < 0.08 for
all comparisons). A 5000 Da PEG chain showed an order of magnitude decrease in activity relative to a 3400 Da
counterpart. Molecular dynamics computational simulations were used to explore the mechanisms of this decreased
activity. Assays were also conducted to demonstrate the utility of a living radical photopolymerization to create
functional, polymeric surfaces with these monomers and to demonstrate surface-based activity against Staphy-
lococcus epidermidis. In particular, the vancomycin-PEG-acrylate derivatives demonstrated a 7-8 log reduction
in bacterial colony forming units (CFU) with respect to nonfunctionalized control surfaces.
Introduction
The function of implantable biomaterials is in large part
governed by material surface characteristics, and chemical
modiﬁcation with pharmaceutically inspired polymers at the
implant-tissue interface is an attractive option for addressing
various biological problems such as postsurgical infection. As
newly engineered biomaterials ﬁnd their way into clinical usage,
issues related to the treatment and prevention of foreign-body-
related bacterial and fungal infections will continue, and new
challenges may be encountered as novel biomaterial-tissue
interfaces are designed and characterized.
1 Polymerizable
derivatives of traditional antibiotics offer the potential for
functionalizing various biomedical materials with the intent of
killing local pathogenic organisms. These chemical species, as
a class, potentially provide great ﬂexibility for engineering
surface architecture, which is thought to strongly inﬂuence
properties such as protein adsorption, cell adhesion (native and
pathogenic), and osteointegration.
2-4 However, to immobilize
these species onto surfaces, one must consider conjugation
methods in addition to monomeric structural characteristics.
A wide assortment of antibacterial polymers exists, but the
majority are based on various inorganic functionalities rather
than on classical, internally administered therapeutics. Most rely
on cationic functionalities that interfere with microbial cell
membranes and ultimately cause release of cellular constituents
(ion leakage) and cell death; phosphonium (P+HR3),
5-7 and
quaternary amine (N+HR3)
7-11 functionalities are common.
Polymers presenting phenol derivatives
12-14 and polycationic
chitosan polymers
15,16 have also been synthesized. N-halamine-
containing polymers that transfer oxidative halogens (Cl+ or
Br+) directly to cell membranes and cause rapid cell death also
exist.
17-20 While these materials ultimately may be useful for
functionalizing implantable biomaterials, it is likely that safety
issues related to host cellular toxicity will continue to be of
concern.
Examples of synthetic polymers based on traditional antimi-
crobials include ﬂuoroquinolones,
21-24 various antifungals,
25-27
ampicillin,
28 and vancomycin.
29-31 However, with the exception
of the vancomycin-based platforms, these approaches presum-
ably rely on the release of active species (i.e., parent drug or
polymer degradation products). Thus, there has been little need
to deﬁne monomer and polymer architectures important for
presenting polymerized antibiotic species to microbial cells.
Such features are particularly important when the antibacterial
system is designed to act through a contact-mediated mechanism
independent of chemical elution, such as in the vancomycin-
based platform described here.
Vancomycin is the prototypical glycopeptide antibiotic, and
it remains potent against gram-positive organisms commonly
encountered in association with indwelling medical devices
(Staphylococcus spp.) such as orthopedic hardware, although
resistance can occur.
32 It derives its activity from binding D-Ala-
D-Ala repeats found at the terminal end of peptidoglycan
precursors. Vancomycin blocks the action of both transglyco-
sylases and transpeptidases by complexing with their substrates
and preventing proper cross-linking of peptidoglycan structures
in the bacterial cell wall.
33 Vancomycin forms several hydrogen
bonds with D-Ala-D-Ala peptidoglycan precursors (Figure 1A),
and internalization is not required for activity. Many glycopep-
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33-37 These
dimers involve intermolecular hydrogen-bonds between adjacent
peptide backbones (Figure 1B) as well as interactions between
sugar residues (Figure 1C).
33-35,37 It has been suggested that
Figure 1. (A) Vancomycin forms multiple hydrogen bonds (dashed lines) with bacterial peptidoglycan precursors and blocks the action of
transpeptidases and transglycosylases. (B) Higher-order interactions also play a role in the mechanism of action. Dimers formed through hydrogen
bonds along the peptide backbone allow for cooperative substrate binding effects. (C) It has been suggested that hydrophobic interactions
between glucose unit C-H groups also play a role in dimer stabilization.
2222 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.this leads to cooperative ligand binding by increasing the
effective antibiotic concentration in the vicinity of other
ligands.
33 A wide literature exists describing the glycopeptides,
their mechanism of action, and combinatorial approaches to
increasing their potency,
33-47 potentially facilitating the cogent
design of new polymerizable analogs. Of note, Arimoto et al.
ﬁrst described vancomycin-based norbornene monomers syn-
thesized through a ring-opening metathesis polymerization with
a Grubb’s ruthenium catalyst.
30,31 It was demonstrated that a
polymer mixture containing 2 to ca. 15-mers was capable of
restoring antibacterial activity against vancomycin resistant
enterococcus (VRE). However, structural analysis of monomers
and polymers was limited.
Beyond understanding the inﬂuence of the synthetic func-
tionalization chemistry on vancomycin activity, a second
important aspect requires characterization of bactericidal activity
of copolymers formed from these polymerized molecules.
Surface-mediated polymerization through an iniferter-based
chemistry is an attractive option for biomaterial surface modi-
ﬁcation. Iniferter surface techniques provide a facile means to
modify materials with desired functional groups.
48-52 Many
iniferters are dithiocarbamate (DTC) derivatives that, upon
homolytic bond cleavage, yield a reactive carbon radical and a
dithocarbamyl radical. The carbon radical readily reacts with
vinyl monomers (e.g., acrylates), whereas the dithiocarbamyl
radical reacts only minimally.
53-55 However, the dithiocarbamyl
radical does reversibly terminate growing polymer chains
(“capping/decapping”) and, depending on reaction conditions,
leads to controlled free-radical polymerization (Figure 2).
48,51,53,56
Recently, we reported the synthesis of a polymerizable,
poly(ethylene glycol)(PEG)-acrylate derivative of vancomycin.
This species was successfully polymerized to an orthopedic
titanium alloy to form a bactericidal surface.
29 However, no
systematic evaluation of monomer structure was conducted,
particularly in relation to biochemical function. We hypothesize
that both the length of the PEG spacer and the site of
vancomycin functionalization will affect solution-based and
surface-based antibacterial activity through several possible
mechanisms. These include interference with speciﬁc hydrogen
bonds important for binding D-Ala-D-Ala, as well as blocking
of vancomycin dimer formation. Here, we also investigate the
effects of monomer composition (relative concentration of the
polymerizable vancomycin analogue to the comonomer) and
monomer structure (PEGylated versus non-PEGylated monomer
and also the site of vancomycin modiﬁcation) on surface-based
antibacterial activity using bioassays with Staphylococcus
epidermidis bacteria.
Materials and Methods
Synthesis of PEG-Acrylate and Acrylamide Vancomycin Deriva-
tives. Vancomycin-PEG(X)-acrylate [VPA(X)] derivatives (where X
) the number average molecular weight of the PEG chain, either 3400
or 5000) were synthesized with slight modiﬁcation from a previous
protocol.
29 Brieﬂy, vancomycin hydrochloride (Sigma Aldrich, St.
Louis, MO) was reacted with N-hydroxysuccinimide-PEG(X)-acrylate
[NHS-PEG(X)-acrylate] (Nektar Therapeutics, San Carlos, CA) in a
4:1 ratio for 24 h in anhydrous dimethyl sulfoxide (DMSO) at room
temperature (Figure 3).
Vancomycin-acrylamide derivatives were synthesized (Figure 4)
by two different procedures. When V3-modiﬁed vancomycin was
desired, vancomycin hydrochloride was dissolved in deionized H2O
and the pH was adjusted to 10.5 by addition of NaOH. The solution
was then frozen and lyophilized. When dry, the lyophilized powder
was dissolved in anhydrous DMSO. Separately, equal volumes of N,N′-
diisopropylcarbodiimide (DIC) (Sigma Aldrich, St. Louis, MO) and
acrylic acid (Fisher Scientiﬁc, Pittsburgh, PA) were reacted in anhydrous
DMSO for ca. 20 min. Following formation of a reactive O-acylisourea
intermediate, this solution was added to the previously prepared
vancomycin solution and vortexed for3ha troom temperature to give
vancomycin acrylamide derivatives (V3 and X1 functionalized). Condi-
tions were chosen to provide for a maximum 2:1 ratio of O-acylisourea
intermediate to vancomycin. The reaction was terminated by addition
of H2O. When X1-modiﬁed vancomycin was desired, an analogous
procedure was followed without the initial pH adjustment.
Liquid Chromatographic Product Puriﬁcation. To remove DMSO
and residual vancomycin, VPA(X) derivatives were puriﬁed by 24 h
dialysis against 1 M NaCl followed by 24 h against deionized H2O
using 3,500 molecular weight cutoff dialysis cassettes. Dialysis was
Figure 2. Living radical photopolymerization using DTC species provides a convenient means of controlling surface properties and studying
their effects on, for example, the antibacterial activity of polymerizable antibiotics. (A,B) Dithiocarbamyl species are cleaved by UV light to form
surface-attached carbon radicals as shown in panel B. (C) When monomer is included in the system, polymer chains grow from the surface.
They are continually terminated and reinitiated (“capping/decapping”) in the presence of UV light, creating a dynamic equilibrium which, in
principle, decreases polydispersity of polymer chains and reduces undesirable chain transfer and chain termination events. Surface-grafted
polymer chains lengthen as polymerization time is increased.
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on a Sephadex G-50F (Amersham Biosciences, Uppsala, Sweden)
column with dimensions 33 cm × 2.5 cm (length × i.d.) and deionized
H2O as the mobile phase. Products were recovered by spectrophoto-
metric analysis of column breakthrough at 220 nm using a Lambda 40
UV/vis spectrophotometer (PerkinElmer Instruments, Wellesley, MA).
Appropriate fractions were collected, frozen, and lyophilized before
further analysis.
Vancomycin acrylamide derivatives were puriﬁed by high-pressure
liquid chromatography (HPLC) using a SymmetryPrep C18 reverse-
phase column of dimensions 19 × 300 mm on a DeltaPrep 4 HPLC
system (Waters Corporation, Milford, MA). All solvents were HPLC-
grade with 0.1% (v/v) triﬂuoroacetic acid to limit product aggregation.
Following the synthetic procedures described above, crude product was
loaded onto the column and run with an appropriate acetonitrile/H2O
gradient. Product peaks were collected by dual-wavelength spectro-
photometric detection at 220 nm and 280 nm. Recovered products were
frozen, lyophilized, and examined for purity on a Symmetry analytical
reverse-phase C18 column of dimensions 4.6 × 150 mm again using
an appropriate solvent gradient.
Matrix-Assisted Laser Desorption Ionization Mass Spectrometry
(MALDI-MS). MALDI-MS was used to conﬁrm product isolation
following liquid chromatography. The matrix solution for all samples
was saturated 2-(4-hydroxyphenylazo)benzoic acid (Fluka, St. Louis,
MO) in 50:50 spectrophotometric-grade methanol and HPLC-grade
water. A Voyager-DE STR BioSpectrometry Workstation mass spec-
trometer (PerSpective Biosystems, Waltham, MA) was used for data
acquisition.
Nuclear Magnetic Resonance (NMR) Spectroscopy. 500 MHz 1H
NMR spectra were obtained for all polymerizable antibiotic monomers
in either DMSO-d6 or D2O on a Varian Inova-500 spectrometer (Varian,
Inc., Palo Alto, CA) at product concentrations of ca. 20 mg/mL. Two-
dimensional (2D) NMR experiments were conducted with vancomycin
acrylamide species to determine the site of acrylamide functionalization.
These experiments included gradient-selected correlation spectroscopy
(gCOSY), heteronuclear single quantum coherence (gHSQC) spectros-
copy, and heteronuclear multibond correlation (gHMBC) spectroscopy.
Minimum Inhibitory Concentration (MIC) and Minimum Bac-
tericidal Concentration (MBC). MIC and MBC values for each
monomer were determined in at least triplicate by the broth dilution
method as described elsewhere.
29 The MIC was deﬁned as the lowest
antibiotic concentration at which no turbidity was observed in growth
suspensions. The MBC was taken to be the lowest monomer concentra-
tion at which 99.9% of the initial bacterial inoculum was killed.
In the case of the VPA(X) species, two computational corrections
were made to the experimentally determined MIC values to account
for: (1) unfunctionalized PEG(X)-acrylate not removed by size exclusion
chromatography; and (2) a small amount of residual vancomycin (ca.
0.4 wt % of the ﬁnal product). Residual vancomycin was determined
by HPLC with peak integrations by Simpson’s Rule.
57 Residual
PEG(X)-acrylate was estimated by 1H NMR integrations. The PEG(X)-
acrylate correction was made by multiplying the total number of moles
of MIC material [moles PEG(X)-acrylate plus moles VPA(X)] by the
mole fraction of VPA(X) (decimal % product by NMR). It is assumed
that PEG(X)-acrylate has computationally insigniﬁcant antibacterial
activity, which is consistent with previous studies showing PEG(400)
to have a MIC of ca. 4000 µg/mL against S. aureus
58 and p-hydro-
xyphenyl acrylate to have a MIC of ca. 625 µg/mL against S.
epidermidis.
59 Moreover, potential probiotic effects of oligoethylene
oxide should be of negligible concern as the only known aerobic, gram-
Figure 3. (A) Vancomycin is typically modiﬁed at one of three sites (dashed circles). The glycosidic primary amine is termed the V3 position, and
the nonamide secondary amine is termed the X1 position. Three structural abbreviations are shown and will be used in subsequent ﬁgures. (B)
VPA(X) species were synthesized using NHS-PEG(X)-acrylate, a reactive ester that favors reaction with primary amines over secondary amines.
2224 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.positive, PEG-degrading bacteria cover some species in the genera
Rhodococcus, Williamsia, Bacillus, Mycobacterium, and Pseudonoca-
dia.
60 Nevertheless, PEG(X)-acrylate does lead to a systematic,
gravimetric error in MIC determinations. Following PEG(X)-acrylate
correction, the result was adjusted for residual vancomycin according
to
where Cvanco (µmol/L) is the concentration of residual vancomycin in
the experiment, MICvanco (µmol/L) is the previously determined MIC
value for vancomycin, CVPA(X) (µmol/L) is the true concentration of
VPA(X) necessary to inhibit bacterial growth in the presence of
contaminating vancomycin, and MICVPA(X) (µmol/L) is the MIC value
for VPA(X). This expression simply assumes that the effects of
vancomycin and VPA(X) are additive in the absence of synergistic
behavior. However, what is measured in the experiment is the total
amount of material added to the culture tube:
Thus, after combination and rearrangement,
This correction is necessary because MICvanco tends to be a small
value for most Staphylococcus species. MBC values were corrected in
an analogous fashion. Error estimates were computed using standard
propagation of uncertainty equations described elsewhere
61 to ensure
that the most conservative (largest) error estimates were calculated.
For these propagation of uncertainty calculations, the following
underlying errors were assumed: 10% error in NMR integrations (a
typical maximum error estimate); 10% error in residual vancomycin
estimates (estimated maximum HPLC error); 10% error in the vanco-
mycin MIC value.
Molecular Dynamics Simulations. Molecular modeling of poly-
merizable vancomycin derivatives was conducted using the molecular
mechanics feature of CS Chem3D Pro v. 7.0 (CambridgeSoft, Cam-
bridge, MA) with the intent of exploring conformational energy minima.
Structures were imported from CS ChemDraw v. 7.0 (CambridgeSoft,
Cambridge, MA), and the energy minimization routine was run with a
root-mean-square (rms) gradient of 0.100. Molecular dynamics simula-
tions were then run at 330 K (37 °C) with a step interval of 2.0 fs, a
frame interval of 10 fs, and a heating rate of either 0.0 or 1.0 kcal/
atom/ps. Simulations were stopped after 10 000 steps. Speciﬁc atomic
separation distances were followed (e.g., between the acrylamide
carbonyl of VA-2 and a local amide hydrogen known to hydrogen-
bond with bacterial D-Ala-D-Ala), and the energy minimization routine
was performed beginning at frames of interest to explore various local
energy minima.
DTC Substrate Preparation. DTC grafting substrates were prepared
from monomer formulations consisting of aromatic urethane diacrylate
(UDA) (Cytec-Surface Specialties, Smyrna, GA) and triethylene glycol
diacrylate (TEGDA) (Sartomer, Exton, PA) mixed with 1 wt %
tetraethylthiuram disulﬁde (TED) (Sigma-Aldrich, St. Louis, MO) and
1.5 wt % 2,2-dimethoxy-2-phenylacetophenone (DMPA) (Ciba-Geigy,
Hawthorne, NY) photoinitiator as described eleshwere.
62 The substrate
was photopolymerized by exposure to a 45 mW/cm2 intensity, col-
limated, broad-range, UV light (Hg arc-lamp centered at 365 nm) for
900 s using a Hybralign Series 200 mask alignment system (Oriel
Instruments, Stratford, CT). These exposure conditions yield a poly-
Figure 4. Vancomycin-acrylamide species were synthesized using carbodiimide chemistry. To minimize side reactions, the reactants for (1)
are allowed to prereact before vancomycin is added. This reduces activation of the vancomycin carboxylic acid by DIC and subsequent side
reactions. DIC chemistries are preferred over NHS esters for reactions at secondary amines and, thus, provided a means for synthesis of both
VA-1 and VA-2. Although not illustrated here, it is possible to obtain polymerizable vancomycin dimers using DIC chemistries, which may be
useful in light of the importance of dimers in glycopeptide antibiotic function.
Cvanco
MICvanco
+
CVPA(X)
MICVPA(X)
) 1 (1)
CVPA(X)
obsd ) CVPA(X) + Cvanco (2)
MICVPA(X) ) (CVPA(X)
obsd - Cvanco) ·(1 -
Cvanco
MICvanco)
-1
(3)
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the acrylate double bond absorbance peak by near-IR spectroscopy.
62
Once polymerized, substrate samples were washed in copious amounts
of methanol to remove any unreacted species prior to the photografting
procedure.
Photografting of VPA(X) and Vancomycin Acrylamides. Poly-
merizable vancomycin derivatives were covalently photografted from
the DTC-functionalized substrate surfaces using iniferter-based pho-
topolymerization chemistry. Grafting solutions were created by dis-
solving VPA(3400) to a concentration of 200 mg/mL (true concentra-
tion) in Ar-purged DMSO then serially diluting with PEG(375)-acrylate/
DMSO solutions of desired composition. Final graft solutions were
targeted to desired molar ratios of VPA(3400)/PEG(375)-acrylate (e.g.,
1:50, 1:100, etc.). VPA(5000) grafting solutions were made in an
analogous fashion. Surfaces were modiﬁed by photopolymerization of
40 µL of a comonomer solution initiated by exposure to the light source
described above for 300 s. A patterned region (3 × 3 array of squares
having dimensions 0.5 cm × 0.5 cm ×∼ 5 µm height) of grafted
antibiotic/comonomer was formed using photolithographic techniques
also described in part elsewhere (Figure 5A,B).
62 The resulting polymers
have a polyacrylate backbone with pendant ethylene glycol units and
pendant vancomycin or PEG(X)-vancomycin (Figure 5C). Following
polymerization, surfaces were washed with copious amounts of ethanol.
An extended elution series consisting of ethanol, sodium chloride, and
deionized water soaks was employed for ca. 24 h to remove any
entrapped or aggregated antibiotic monomer. Surface grafts were then
characterized by proﬁlometry using a Dektak 6 M Stylus Proilometer
(Veeco Instruments, Inc., Woodbury, NY) to determine graft thickness.
Vancomycin acrylamide graft polymerizations were conducted in an
analogous fashion.
Surface Antibacterial Assays. Using aseptic technique, grafted
squares (elements of the aforementioned 3 × 3 arrays) of antibacterial
copolymers were isolated with a hydrophobic PAP pen and exposed
t oa4 0µL aliquot of brain heart infusion (BHI) media containing 1 ×
104 colony forming units (CFU)/mL S. epidermidis ATCC 12228
(MicroBiologics, Inc., St. Cloud, MN) for 20 h at 37 °C. This surface
challenge time was chosen to simulate the initial bacterial seeding as
might occur following the implantation of orthopedic hardware and to
demonstrate bactericidal activity. It is acknowledged that, under some
in vivo conditions, surfaces will be challenged for longer periods of
time and challenged repeatedly. Following incubation, the suspensions
were sampled, serially diluted with sterile, deionized water, and plated
on trypticase soy agar with 5% sheep blood (Becton, Dickinson, and
Co., Sparks, MD) for CFU counts. Various surface densities of
polymerizable antibiotic were assayed for activity. Activity was reported
in terms of log reduction relative to nonantibiotic control surfaces.
Figure 5. (A) Photolithographic techniques were used to pattern antibacterial polymer on a DTC-functionalized surface. UV light passes through
the transparent regions of the photomask (squares) and polymerizes the underlying monomer solution containing polymerizable antibiotic and
an appropriate comonomer. (B) Polymer squares are grafted from the surface and are used for testing polymer antibacterial activity. The inset
shows a proﬁlometry trace through three grafted squares. Grafts on the order of 5 µm thickness were used throughout the experiments described
here. This is about 5 times the diameter of a S. epidermidis organism. (C) Shown is the expected dominant polymer structure when a VPA(X)
monomer is copolymerized with PEG(375)-acrylate. A polyacrylate backbone is formed by chain polymerization. Pendant to the backbone are
both PEG(375) functionalities (m ∼ 9) and vancomycin-PEG(X) groups (n ∼ X/44, where 44 g/mol is the molecular weight of an ethylene glycol
repeat). To a ﬁrst approximation, the spacing between vancomycin groups (“spacing along backbone”) is given by the ratio of VPA(X):PEG(375)-
acrylate in the monomer solution.
2226 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.Elution controls were employed to differentiate surface-based activity
from simple release of antibiotic moiety (see below).
Elution Controls. Elution controls were conducted using bioassays
similar to those described previously
29 to verify that no detectable
vancomycin was released from the grafts over a time frame com-
mensurate with the surface antibacterial assays. For each grafted 3 ×
3 array of test squares, at least one control square was exposed to a
sterile 40 µL aliquot of BHI media that was coincubated with the other
bacteria-exposed squares. Following incubation, 10 µL of this media
were collected, frozen, lyophilized, then inoculated with 10 µL
deionized water containing 1 × 104 CFU/mL of the test organism. The
solution was incubated for 20 h at 37 °C, and a visibly positive culture
was taken as indicative of undetectable antibiotic elution.
Statistical Analysis. All statistical calculations were performed using
Minitab15 statistical software (Minitab, Inc., State College, PA). MIC
and MBC data are most properly compared using a nonparametric
method such as the Mann-Whitney test, which makes no assumption
about an underlying distribution and is appropriate for discrete data.
However, our raw VPA(X) data required a propagation of uncertainty
calculation following adjustment for residual PEG(X)-acrylate and
residual vanocmycin (see eqs 1-3). Thus, statistical comparisons of
MIC and MBC parameters were calculated by both the Mann-Whitney
test using raw data and the student t test using propagation of uncertainty
information. In general, both methods were in good agreement with a
chosen R)0.1. Reported P values are the more conservative (larger)
for a given comparison.
Results and Discussion
Implantable devices have become common in most ﬁelds of
medicine, and various design issues including tissue integration,
immunogenicity, and material degradation must be considered.
Regardless of implant type, infections secondary to microbial
colonization remain a signiﬁcant clinical concern. Thus, there
has been an increased interest in developing new materials for
either delivering antibiotics locally
63-67 or for surface-modifying
biomaterials with antibacterial functionalities.
29,68-70 Polymer-
izable derivatives of traditional antibiotics offer potential for
controlled biomaterial surface modiﬁcation. Here, we describe
the synthesis and characterization of several monomeric van-
comycin derivatives and relate MIC data to structural charac-
teristics of various monomers through both 2D NMR techniques
and molecular dynamics simulations. We conclude with an
iniferter-based platform for ascertaining structure-function
biochemical relationships of polymerized constructs with the
ultimate goal of facilitating the trenchant design of polymeriz-
able, surface-active antimicrobials and other pharmaceutical
species.
Synthesis and Characterization of Monomers. Two
vancomycin-PEG-acrylate species and two vancomycin acryl-
amide species (Figure 6) were synthesized.
The PEG-acrylate derivatives differ in the molecular weight
of the PEG chain (number average molecular weight ∼3400
g/mol versus ∼5000 g/mol), and the acrylamides differ at the
site of vancomycin modiﬁcation (glycosidic primary amine at
the V3 position versus the lone, nonamide secondary amine at
the X1 position) (Figure 3A). These species are in some sense
similar to the norbornene derivatives described by Arimoto et
al.;
30,31 however, the compounds described there were modiﬁed
solely at the V3 position without PEG linkers. Moreover, the
subsequent polymerization scheme relied upon a ruthenium
Grubb’s catalyst and required approximately 1.5 days to yield
useful polymeric material, whereas the current approach achieves
bactericidal polymers on the order of minutes.
Consistent with our VPA(X) synthesis protocol, size exclusion
liquid chromatography results (not shown) demonstrated two
peaks for a given VPA(X) type: a lead peak at ca. 25 min
containing high molecular weight compounds that eluted with
the void volume (conﬁrmed with blue dextran); and a product
peak at ca. 30 min for VPA(5000) or ca. 35 min for VPA(3400).
The absence of a third peak suggests that the dialysis procedure
removed most residual vancomycin and small-molecule species.
The high molecular weight byproducts (lead peak) in our
synthesis scheme likely represent products formed by autopo-
lymerization of monomer based on 1H NMR results (not shown).
In the case of VPA(3400), MALDI-MS indicated that the
Figure 6. (A) PEG-acrylate derivatives of vancomycin potentially offer advantages related to PEGylation while at the same time allow for facile
polymerization to biomaterial constructs through the acrylate group. Here, we present two such species, one having a 3400 molecular weight
PEG spacer and the other having a 5000 molecular weight spacer. The molecular weight of an ethylene oxide repeat is 44 g/mol. (B) Vancomycin
acrylamide derivatives are structurally similar but lack the PEG spacer. VA-1 is modiﬁed at the glycosidic primary amine of vancomycin. (C)
VA-2 is modiﬁed at the sole nonamide secondary amine.
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3500 g/mol molecular weight [residual PEG(3400)-acrylate] and
a polymeric species of ca. 4800 g/mol molecular weight
[VPA(3400)]. A repetitive 44 g/mol spacing was noted through-
out the molecular weight distributions, which is characteristic
of PEG polymers: the polydispersity index (PDI) of NHS-
PEG(3400)-acrylate used in the synthesis was ca. 1.03. A similar
result was obtained with VPA(5000), but the central molecular
weights were shifted to 5000 g/mol and 6500 g/mol; the PDI
of NHS-PEG(5000)-acrylate used in the synthesis was ca. 1.05.
Analytical HPLC results obtained following the vancomycin
acrylamide synthesis protocol(s) showed that each of the
recovered materials eluted as a dominant, symmetric peak with
only low-level contamination (estimated at >95% purity).
However, the retention times differed by ca. 3 min. MALDI-
MS results indicated that these two peaks were of the same
molecular weight (Figure 7B,D), which suggested that one
species was VA-1 and the other VA-2. MALDI-MS also showed
that puriﬁed VA-1 contained some residual material attributed
to aglucovancomycin (both sugars removed) (Figure 7B) and
desvancosaminylvancomycin (terminal sugar removed), which
is consistent with species known to be present in commercially
available vancomycin preparations.
38 The VA-2 peak contained
residual material attributed to aglucovancomycin acrylamide
(Figure 7D).
1H NMR characterization of the VPA(X) species demon-
strated the expected functionalities. Using VPA(3400) as an
example, chemical shifts were as follows: vinyl hydrogens from
the acrylate (δ ) 6.0, 1H, doublet; δ ) 6.2, 1H, multiplet; δ )
6.4, 2.7H, doublet, convoluted with aromatic Hs); PEG hydro-
gens (δ ) 3.4 - 3.8); aromatic hydrogens from vancomycin
(δ ) 6.4 - 7.8); and methyl hydrogens from vancomycin (δ )
0.9, 3.7H, doublet). Six methyl hydrogens are expected for pure
VPA(X), indicating that the recovered material was approxi-
mately 60% VPA(3400) and 40% PEG(3400)-acrylate. The
acrylamide derivatives gave similar spectra without the PEG
peak. The pertinent vinyl and methyl integrations and compari-
sons to calculated values are presented below (Table 1).
To determine the site of acrylamide functionalization on
vancomycin acrylamide derivatives, 2D NMR experiments were
conducted. gCOSY spectra for VA-2 are shown below (Figure
8A-B). Off diagonal peaks represent correlations between
hydrogens on adjacent carbons, while the peaks on the diagonal
are representative of the corresponding 1H shifts. The gCOSY
spectra revealed the presence of an acrylamide functionality.
Figure 7. (A,C) C18 analytical reverse phase HPLC with VA-1 and VA-2 showed that the products were clean (>95%). (B,D) MALDI-MS showed
the expected Na+ peaks in addition to low-level contamination from various vancomycin-type species such as aglucovancomycin, desvan-
cosamiylvancomycin, and aglucovancomycin acrylamide.
Table 1. MALDI-MS, Liquid Chromatography, and 1H NMR Results for the Four Polymerizable Vancomycin Derivatives
NMR integrations relative to a vinyl H
species
m/z+
(calcd, Na+)
m/z+
(obsd, Na+)
HPLC rt
(min.) gel ﬁltration rt (min.) solvent
methyl H’s
(calcd)
methyl H’s
(obsd)
methyl (obsd)/
methyl (calcd)
% product
by NMR
vancomycin 1473.3 1472.7 16.5 variable
(aggregationeffects)
DMSO 6.0 6.0 1.00 100%
VPA(3400) ca. 4900 ca. 4800 35 D2O 6.0 3.7 0.62 62%
VPA(5000) ca. 6500 ca. 6500 30 D2O 6.0 3.3 0.55 55%
VA-1 1527.3 1526.9 18.2 DMSO 6.0 6.0 1.00 100%
VA-2 1527.3 1526.8 21.1 DMSO + D2O 6.0 5.6 0.93 93%
2228 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.Figure 8. (A) gCOSY spectrum of VA-2. Correlations between vinyl protons are shown (dashed circles, arrows, and lines). (B) A more complete
gCOSY spectrum of VA-2 allowed for assignment of 1H chemical shifts along part of the aliphatic backbone of the molecule. Three correlations
are shown (dashed circles and lines). (C) gHSQC experiments which establish correlations between 13C and 1H nuclei were used to assign
pertinent 13C shifts once the 1H shifts were known. (D) A gHMBC experiment was used to establish correlations between 13C nuclei and 1H
nuclei up to three bonds distant. Here, four important correlations are noted (dashed circles) that place the N-CH3 group along the previously
deﬁned molecular backbone as well as establish its vicinity to the carbonyl of the acrylamide group. These correlations deﬁnitively place the
acrylamide group at the vancomycin X1 position.
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in conjunction with gHSQC and gHMBC NMR spectroscopy.
A complete gCOSY and a gHSQC spectra are shown below
for VA-2 (Figure 8B,C). gCOSY analysis allowed for the
determination of the chemical shifts of hydrogens along the
vancomycin molecule starting from the known methyl hydrogen
shift at 0.9 ppm. The relevant 1H shifts are illustrated (Figure
8B). gHSQC establishes correlations between carbon atoms and
their attached hydrogens. Thus, gHSQC was used to identify
the 13C shift (54.5 ppm) of the tertiary carbon directly bound to
the vancomycin X1 secondary amine (Figure 8C).
gHMBC, optimized for correlations between carbons and
hydrogens three-bond distance, was used to establish the 1H
shift of the N-CH3 hydrogens at the X1 position as well as to
correlate the carbonyl of the acrylamide to the N-CH3
hydrogens, deﬁnitively establishing that VA-2 is the X1-modiﬁed
vancomycin acrylamide derivative (Figure 8D). A similar
analysis (not shown) with VA-1, established that VA-1 was the
V3-modiﬁed acrylamide species.
Our VPA(X) synthesis procedures made use of N-hydrox-
ysuccinimidyl ester starting reagents of a type that readily reacts
with primary amines and less readily with secondary amines
and alcohols. The esters formed by the reaction with alcohols
are unstable and readily hydrolyze.
71 Thus, our VPA(X) species
should be primarily of the V3-modiﬁed type, which places the
PEG linker opposite the binding pocket of the vancomycin
molecule. 1H NMR conﬁrmed that our synthesized VPA(X)
molecules did have both PEG-acrylate and vancomycin func-
tional characteristics, and MALDI-MS results suggest that we
were able to recover singly functionalized VPA(X) using a
Sephadex G-50F size exclusion column. Likewise, the synthetic
approach used to construct vancomycin acrylamide monomers
made use of well-established chemistries of the carbodiimide
variety.
71 The main drawback of these chemistries is the
relatively high reactivity of O-acylisourea intermediates and the
possibility of side reactions. However, some control was
afforded through optimization of reactant stoichiometry and
reaction times, and we were able to isolate the desired
vancomycin acrylamide derivatives (VA-1 and VA-2) as
conﬁrmed by analytical HPLC, MALDI-MS, and various NMR
techniques. In conjunction with proper HPLC protocols, car-
bodiimide chemistry offers an opportunity to isolate several
interesting and potentially bioactive species. Polymerizable
vancomycin dimers, for example, might offer increased potency
with respect to the species presented here in light of other studies
with multivalent antibiotics.
39,43,45
Molecular Dynamics Simulations. Molecular dynamics
simulations with VA-2 at 37 °C and no heat input indicated
that the acrylamide carbonyl oxygen assumes a local energy
minimum when placed within 1.9-2.1 Å of an amide hydrogen
located on the vancomycin backbone. This hydrogen normally
plays a role in H-bonding bacterial D-Ala-D-Ala, suggesting that
adding an acrylamide to the vancomycin X1 position competi-
tively blocks this interaction (Figure 9A). When heat was added
to the system at a rate of 1.0 kcal/atom/ps, adequate energy
was afforded for the molecule to escape this conformation.
However, the ca. 2.0 Å separation still remained a favorable
conformational energy minimum.
Molecular dynamics simulations with VPA(X) species did
not point to a single molecular conformation that was responsible
for decreased activity. It was found that with a long PEG linker
(ca. 80 repeat units were used in simulations), there existed
almost endless energetically favorable geometries between the
vancomycin moiety and the attached PEG chain. Twisted, coiled,
and linear structures were all reasonable, and no particular
energy minimum was favored. However, these results demon-
strated the extensive mobility of the PEG linker that may
ultimately provide an explanation for the observed activity data.
MICs and MBCs. MIC values for all polymerizable van-
comycin derivatives were increased (P < 0.08 for all compari-
sons) relative to vancomycin, ranging from 7 ( 1 µMt o6 7(
20 µM (Table 2). MBC values were similarly increased. In
general, the intuitive interpretations from Table 2 were correct.
The speciﬁcs are as follows: the VA-1 MIC was less than the
VA-2 MIC (P ) 0.01); the VA-1 MIC was not statistically
different from the VPA(3400) MIC (P ) 1), but was less than
the VPA(5000) MIC (P ) 0.05); the VA-2 MIC was higher
than the VPA(3400) MIC (P ) 0.03), but was not statistically
different from the VPA(5000) MIC (P ) 0.14); and the
VPA(3400) MIC was less than the VPA(5000) MIC (P ) 0.08).
MBC comparisons were analogous. Of note is that the VA-1
MBC was statistically greater than its MIC (P ) 0.05). VA-2
showed a similar result (P ) 0.03). However, the VPA(3400)
MBC was not statistically greater than its MIC (P ) 0.3), nor
was there a difference for the VPA(5000) pair.
The 2D NMR data described above offers a unique op-
portunity to correlate antibiotic activity data in the form of MIC
values with known biochemical structural relationships. Data
strongly suggest that the decreased activity observed with VA-2
versus VA-1 (MIC of 39 µM versus 7 µM, respectively) is the
result of interference with a single hydrogen bond normally
made with bacterial peptidoglycan D-Ala-D-Ala. The acrylamide
carbonyl oxygen of VA-2 is placed within only a few angstroms
of a vancomycin amide important for H-bonding bacterial
peptidoglycan precursors. It is likely that this conformation
allows for competitive, intramolecular blocking of D-Ala-D-Ala
binding (Figure 9A). This hypothesis is substantiated by
molecular dynamics results, which show a conformational
energy minimum when the acrylamide oxygen assumes a
position ca. 2.0 Å from this vancomycin amide hydrogen, a
typical bond distance for amide-amide hydrogen bonds.
More complicated is the observed difference in activity
between VA-1 and vancomycin (both modiﬁed at the glycosidic
primary amine). The decreased activity of VA-1 is most likely
explained in terms of interference with sugar-mediated dimer-
ization whereby the acrylamide makes it sterically more difﬁcult
to form favorable interactions (Figure 9B). It is well-established
that interactions between glycopeptide sugars play a role in
stabilizing dimers,
33-35,37 and it has been suggested that the
vancomycin glucose units interact hydrophobically via axial
C-H groups (Figure 1C, 9B).
35 It has been demonstrated, for
example, that adding groups such as di- or tribenzene funtion-
alities to the glycosidic primary amine of certain glycopeptide
antibiotics, presumably facilitating hydrophobic interactions, can
increase the potency of these species.
72 Moreover, Kannan et
al. demonstrated that acetylation of vancomycin at the glycosidic
primary amine decreases antibacterial activity by approximately
a factor of 12 but only decreases binding afﬁnity to an Ac2-L-
Lys-D-Ala-D-Ala ligand (an analog of bacterial peptidoglycan)
by a factor of 3.
73 These results suggest that modiﬁcation of
the sugar residue does not interfere with the vancomycin binding
pocket but does alter the dimerization constant. We observed
approximately a 6-fold decrease in activity with VA-1, which
is in reasonable agreement considering Kannan used a different
bacterial species and activity assay.
The length of the PEG linker used to connect vancomycin to
a polymerizable moiety also inﬂuences activity. The MIC value
for VPA(5000) was signiﬁcantly higher than that of VPA(3400),
2230 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.indicating decreased activity of the former. One might consider
degradative processes such as hydrolysis (enzymatic or other-
wise) and the resultant fragmentary products when analyzing
this differential activity. However, Staphylococcus spp. are not
known to be PEG degraders,
60 and MIC values for species
Figure 9. There are several possible mechanisms by which functionalization of vancomycin may decrease activity. (A) In the case of VA-2 (X1
functionalization), competitive, intramolecular interference with an hydrogen-bond important for binding bacterial D-Ala-D-Ala is probable based
on molecular dynamics calculations. (B) VA-1 (V3 functionalization) may sterically interfere with glucose units important for dimer stabilization.
Rotation about the illustrated bond could allow such interference. (C) PEG-acrylation of vancomycin at the V3 position may decrease activity by
blocking dimerization and/or by interfering with the vancomycin binding pocket (coiled structure). MIC data suggest the latter is dependent on
PEG chain length. A partially extended VPA(5000) structure is shown for comparison. The Connolly molecular surfaces are drawn to scale, and
the vancomycin head has a molecular diameter of ca. 20 Å.
Table 2. A Summary of MIC and MBC Data
a
antibacterial MIC (µM) MBC (µM)
fold
decreased
activity
b
vancomycin 1.1 ( 0.1, n ) 3 MIC ) MBC 1
VA-1 7 ( 1, n ) 41 7 ( 4, n ) 3 6.4
VA-2 39 ( 4, n ) 66 0 ( 5, n ) 33 5
vancomycin-PEG(3400)-
acrylate
7 ( 1, n ) 39 ( 2, n ) 3 6.4
vancomycin-PEG(5000)-
acrylate
67 ( 20, n ) 37 5 ( 25, n ) 36 1
a In general, the intuitive comparisons are statistically correct. Func-
tionalization at the V3 or X1 position decreases activity relative to
vancomycin. However, modiﬁcation at the X1 site has a more pronounced
effect (VA-2 vs VA-1). Increasing the length of the PEG linker also appears
to decrease activity, presumably after some critical length is passed.
b Ratio of MIC to the MIC of vancomycin.
Table 3. Various Copolymers of Polymerizable Antibiotic (Abx)
and PEG(375)-Acrylate
a
Abx monomer
copolymer molar ratios
Abx:PEG(375)-Acrl log reduction
b
VPA(3400) 1:60 7.0 ( 0.4, n ) 4
1:175 2 ( 1, n ) 4
VPA(5000) 1:60 8 ( 1, n ) 4
1:175 0.0 ( 0.3, n ) 4
VA-1 1:20 0.2 ( 0.4, n ) 4
1:330 0.3 ( 0.3, n ) 4
VA-2 1:20 0.0 ( 0.5, n ) 5
1:330 0.5 ( 1, n ) 4
a The monomer ratios are shown, which provide an approximation of
the spacing between pendant vancomycin molecules along the polymer
backbone. Here, the log reduction in bacterial numbers with respect to
control surfaces [homopolymer of PEG(375)-acrylate] are shown. Of note
is that only the PEG(X)-acrylate vancomycin derivatives showed surface
antibacterial activity. Surfaces were inoculated with approximately 1 ×
104 CFU/mL S. epidermidis ATCC 12228 and grown at 37°C for 20 h.
Final bacterial concentration on control surfaces typically reached 1 ×
107 CFU/mL to 1 × 108 CFU/mL.
b If log reduction ) 7, then the number
of bacteria was reduced by 7 orders of magnitude with respect to the
control surface.
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computationally insigniﬁcant as noted previously. However,
enzymatic ester hydrolysis of certain polymeric dental resins
has been noted,
74 and suggests that issues related to degradation
deserve future exploration. While the mobility of a PEG tether
may ultimately be useful for facilitating interactions with
bacterial cells when a polymerizable antibiotic (or other bio-
molecule) is covalently bound to a surface, that same PEG
mobility may actually lead to twisted and convoluted geometries
that shield the antibiotic from its binding target (Figure 9C) or
interfere with higher-order structures such as dimers. Molecular
dynamics simulations suggest a vast set of energetically
favorable geometries encompassing the vancomycin moiety and
the attached PEG chain, and it naturally follows that the longer
the chain, the more varied the available conformational space.
It appears that lengthening the PEG chain by approximately
50% from ca. 3400 Da to 5000 Da decreases relative activity
by almost an order of magnitude in solution-based assays. This
result suggests that the 5000 Da PEG chain may be of sufﬁcient
length to interfere with dimerization and to block D-Ala-D-Ala
interactions in the vancomycin binding pocket, whereas the 3400
Da PEG chain may only interfere with the former.
Surface-Based Polymer Activity. VPA(3400) when copo-
lymerized with PEG(375)-acrylate demonstrated bactericidal
activity when the ratio of VPA(3400):PEG(375)-acrylate in the
comonomer solution was ∼1:60. Previous results suggest that
a ratio of ∼1:100 is bactericidal as well.
29 To a ﬁrst approxima-
tion, the former ratio implies that, along the newly formed
polymer backbone (polyacrylate backbone), there are ap-
proximately 60 pendant PEG(375) units for every pendant
PEG(3400)-vancomycin species (Figure 5C), assuming random
polymerization of the two monomers.
The photolithographic technique employed here is a
convenient platform for constructing copolymers and for
rapidly assessing their antibacterial properties. The expected
polymer homogeneity in conjunction with improved spatial
and temporal control of surface architectures is desirable for
clarifying structural issues related to antibacterial action. In
experiments described above, relative ratios of comonomers
were varied to change the spacing of active antibiotic species
along the resulting polymer backbone. Other parameters
including polymer backbone length, the nature of the
comonomer pendant functionality, and the hydrophobicity/
hydrophilicity of the tether arm used for antibiotic conjuga-
tion deserve further exploration, in principle by the techniques
described here. Experiments were also conducted with
different polymerizable vancomycin derivatives both with and
without PEG linkers to explore the importance of spatially
separating the active antibacterial moiety from the underlying
polymer architectures. The site at which the vancomycin
molecule was derivatized was also explored with two
vancomycin acrylamide derivatives at the surface interface
level.
For a given antibiotic monomer, a critical copolymer com-
position that deﬁnes bactericidal activity is expected, just as
there is a critical solution concentration that deﬁnes MIC values.
That ratio has not been tightly deﬁned for the species presented
here, but it has been determined with sufﬁcient precision to relate
surface-based and solution-based activity of monomers. Al-
though VPA(5000) has a MIC approximately an order of
magnitude higher than that of VPA(3400), it shows surface-
based bactericidal activity at approximately the same graft
composition (Table 3).
This could be the result of multiple biochemical interactions
including (1) decreasing the translational degrees of freedom
of the PEG chain through surface tethering, thus making the
antibiotic binding pocket more accessible; (2) separating the
vancomycin moiety from underlying, interfering polymer ar-
chitectures (Figure 10); (3) simulating cooperative binding
effects, as proposed with conventional vancomycin dimers,
33
by increasing the effective local antibiotic concentration; or (4)
allowing the vancomycin molecule to penetrate some critical
distance into the bacterial peptidoglycan layer. Grafts with VA-1
or VA-2 showed no surface-based activity. This may be related
to structural features of the VA-1 and VA-2 monomers and their
interaction with bacterial cells, or there may be differences in
surface concentration related to steric effects encountered during
polymerization. However, previous work has shown that acry-
lated IgG antibodies with no PEG spacer can be polymerized
in a similar system,
56 as can methacrylated carboxyﬂuorescein
diacetate.
75
Interestingly, the PEG tethers described here can extend
between 200 Å [VPA(3400)] and 300 Å [VPA(5000)], and this
distance corresponds closely to the thickness of the Staphylo-
coccal peptidoglycan layer, which is typically 150-300 Å
thick.
76 These mechanistic possibilities warrant further inves-
tigation.
As a ﬁnal note, there is always concern that, when materials
such as these are employed clinically, this could stimulate the
development of antibiotic resistance. This issue has been
addressed in part previously
29 with the addendum that the
clinical situation would likely guide implementation. For
example, these materials might be very useful for modifying
orthopedic hardware when the bacterial load is not overwhelm-
Figure 10. (A,B) When VPA(X) species are tethered from a surface pendant to a polyacrylate backbone, the translational degrees of freedom
of the PEG chain will be reduced, potentially restoring antibacterial activity and facilitating desired biochemical interactions. (C) When VA-1 or
VA-2 are copolymerized with PEG(375)-acrylate, it is expected that the pendant PEG moieties will block vancomycin interactions with D-Ala-
D-Ala.
2232 Biomacromolecules, Vol. 10, No. 8, 2009 Lawson et al.ing but might be less appropriate in a polymicrobial, high
bacterial load environment such as the oral cavity or gastrointes-
tinal tract.
Conclusions
The facile synthesis, puriﬁcation, and biochemical evaluation
of various polymerizable vancomycin derivatives is presented
with the intent of demonstrating a set of tools useful for
evaluating new biomolecules engineered for surface modiﬁcation
of implantable biomaterials. Site speciﬁc modiﬁcation of the
parent antibiotic was achieved with either PEG-acrylate or
acrylamide functionalities, and the site of modiﬁcation was
found to inﬂuence antibiotic activity. Consistent with well-
established vancomycin mechanisms of action, molecular
dynamics simulations in conjunction with MIC data suggest that
interference with hydrogen bonds in the vancomycin binding
pocket as well as interference with higher-order intermolecular
complexes such as antibiotic dimers must be considered in the
rational design of new polymerizable monomers. An iniferter-
based surface-mediated polymerization was used to synthesize
vancomycin-functionalized copolymers, and the nature of the
tether separating the parent antibiotic from the attached poly-
merizable functionality affected the antibiotic activity. Monon-
tonically decreasing activity was observed with increased PEG
spacer length in solution-based MIC assays; however, experi-
ments with polymerized vancomycin derivatives suggest that
PEG tethers may be useful for separating the antibiotic moiety
from other camouﬂaging polymer architectures and for spatially
enabling desired biochemical interactions. Collectively, the data
and techniques described above demonstrate the need for parsing
structure-function relationships of polymerizable biomolecules
intended for modifying biomaterial devices and for addressing
speciﬁc design features of clinical import.
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